Furthermore, subcutaneous delivery of the nanoformulation enables it to migrate to a draining lymph node, where it stimulates DCs and CD8+ T cells (cytotoxic T cells), resulting in an enhanced anticancer response in bladder, melanoma, and renal carcinoma models, demonstrating the importance of PLGA NPs as effective immunostimulatory adjuvants for cancer immunotherapy [171]. This evidence concerns the gene CD8A and cancer.